Galecto Starts Phase 2 Trial by dosing in Investigator-Initiated Study Combining GB1211

Galecto Starts Phase 2 Trial by dosing in Investigator-Initiated Study Combining GB1211

By, Admin 3 May 2024

Galecto Starts Phase 2 Trial with First Patient Dosed in Investigator-Initiated Study Combining GB1211 and Pembrolizumab

Overview

Galecto, Inc. (NASDAQ: GLTO), a biotech company specializing in pioneering cancer and fibrosis treatments, has reached a significant milestone in its clinical journey. They've initiated an investigator-led Phase 2 trial at the Earle A. Chiles Research Institute (EACRI), part of the Providence Cancer Institute in Portland, Oregon, USA. Led by Dr. Brendan Curti and Dr. William Redmond, the trial will evaluate GB1211, Galecto’s oral galectin-3 inhibitor, in combination with pembrolizumab for treating metastatic malignant melanoma (MM) and head and neck squamous cell carcinoma (HNSCC). Supported by a grant from the National Cancer Institute, Galecto is supplying GB1211 for the trial.

The trial stems from galectin-3's overexpression in various cancers, including melanoma and HNSCC, which correlates with tumor progression and resistance to treatments like pembrolizumab and atezolizumab. GB1211 aims to mitigate these resistance mechanisms by inhibiting galectin-3.

Building upon promising Phase 1b/2a trial results, Galecto aims to explore GB1211's potential in combination with pembrolizumab further. Dr. Curti emphasizes the strength of Providence Cancer Institute's research approach, citing insights from Dr. Redmond’s lab as crucial for this trial.

Dr. Redmond highlights their research into galectin-3's role in tumor immune suppression, expressing enthusiasm for countering ICI resistance with GB1211 and pembrolizumab.

Galecto's CEO, Dr. Hans Schambye, lauds the trial's initiation at Providence Cancer Institute, recognizing Dr. Redmond's expertise and anticipating synergistic benefits from combining GB1211 with pembrolizumab.

Phase 2 Trial

  • The Phase 2 trial, a randomized, double-blind placebo-controlled endeavor, aims to evaluate GB1211's impact on pembrolizumab's response rate in metastatic melanoma and HNSCC patients. 
  • With a focus on assessing both safety and efficacy, the trial will also gather biospecimens to delve into immunological markers relevant to galectin biology and T-cell checkpoint inhibition, with early data anticipated as soon as 2025.

GB1211's Mechanism

  • GB1211's mechanism, designed to counteract galectin-3's adverse effects, has shown promise in preclinical models and Phase 1 trials, positioning it as a potential game-changer in cancer therapy. 
  • Through collaborative efforts like this trial, Galecto aims to advance innovative treatments and improve patient outcomes in cancer and fibrosis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!